Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2018/03/012421
CTRI/2018/03/012421
Recruiting
Phase 3

A single-arm, multicenter phase IIIB clinical trial to evaluate the safety and tolerability of prophylactic Emicizumab in Hemophilia A patients with inhibitors.

F HoffmannLa Roche Ltd0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
F HoffmannLa Roche Ltd
Status
Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
F HoffmannLa Roche Ltd

Eligibility Criteria

Inclusion Criteria

  • •1\. Signed Informed Consent Form
  • •2\. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, including the PRO questionnaires and bleed diaries through the use of an electronic device, as per the investigatorâ??s judgment
  • •3\. Aged 12 years or older at the time of informed consent
  • •4\. Body weight \>\=40 kg at the time of screening
  • •5\. Diagnosis of congenital hemophilia A with persistent inhibitors against FVIII
  • •6\. Adequate hematologic function
  • •7\. Adequate hepatic function
  • •8\. Adequate renal function

Exclusion Criteria

  • •1\. Inherited or acquired bleeding disorder other than hemophilia A
  • •2\. Ongoing (or plan to receive during the study) ITI therapy (prophylaxis regimens with FVIII and/or bypassing agents must be discontinued prior to enrollment).
  • •3\. History of illicit drug or alcohol abuse within 12 months prior to screening, as per the investigatorâ??s judgment
  • •4\. Other conditions (e.g., certain autoimmune diseases) that may increase the risk of bleeding or thrombosis
  • •5\. History of clinically significant hypersensitivity reaction associated with monoclonal antibody therapies
  • •6\. Known human immunodeficiency virus (HIV) infection
  • •7\. Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the patientâ??s safe participation in and completion of the study or interpretation of the study results

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Mifepristone 50mg as a weekly ContraceptivePrevention of unwanted pregnancyTherapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]
EUCTR2020-000866-41-Outside-EU/EEAWomen on Web International Foundation
Completed
Phase 3
A clinical trial to study the effects of epoetin in patients with chronic renal failureHealth Condition 1: N189- Chronic kidney disease, unspecifiedHealth Condition 2: null- Maintaining hemoglobin level in chronic renal failure
CTRI/2008/091/000257Cadila Healthcare Ltd80
Unknown
Not Applicable
A CLINICAL TRIAL PHASE III, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TO EVALUATE THE SAFETY AND EFFICACY OF MK-0431A (TAB OF A FIXED DOSE COMBINATION OF SITAGLIPTIN AND METFORMIN) IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS
PER-117-11MERCK SHARP & DOHME PERU S.R.L.,
Recruiting
Phase 3
A phase III study in ICP (intraheptatic cholestatis of pregnancy) to assess the improvement of pruritis and other liver parameters after treatment with Udiliv tabletsHealth Condition 1: O266- Liver and biliary tract disordersin pregnancy, childbirth and the puerperium
CTRI/2021/08/035635Abbott India Limited
Active, not recruiting
Phase 1
A single arm, multicentre, phase IIIb study to evaluate safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab administered during induction phase or maintenance in previously untreated patients with CD20+ diffuse large B cell lymphoma (DLBCL) or follicular lymphoma (FL)
EUCTR2013-000647-12-ITROCHE S.p.A.158